In a mouse clinical trial consisting of multiple patient- and cell line-derived xenograft models of KRASG12C NSCLC, RMC-6291 outperformed adagrasib, a KRASG12C(OFF) inhibitor, by increasing the number of responses, the depth of tumor regressions, and the durability of responses.Combination ...
“We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly. The RMC-6236 safety data support that this highly innovative, oral RASMULTI Inhibitor is generall...
“We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly. The RMC-6236 safety data support that this highly innovative, oral RASMULTI Inhib...
我们现在正在研究三个高度创新的RAS抑制剂，且它们具有互补的特性——RMC-6236适用于由多种RAS突变引发的癌症患者，而另外两款抑制剂中，RMC-6291的靶点为KRAS G12C，RMC-9805的靶点为KRAS G12D。”参考来源：1. https://doi.org/10.1016/j.annonc.2023.10.025 2. https://www.targetedonc.com/view/rmc...
我们现在正在研究三个高度创新的RAS抑制剂,且它们具有互补的特性——RMC-6236适用于由多种RAS突变引发的癌症患者,而另外两款抑制剂中,RMC-6291的靶点为KRAS G12C,RMC-9805的靶点为KRAS G12D。” 在这项1/1b临床研究中,研究人员将主要评估患者用药...
(RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-0708 (KRASQ61H) and RMC-5127 (KRASG12V) which are currently in IND-enabling development, RMC-8839 (KRASG...
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9...
Further, RMC-6236 has a compelling profile for evaluation in combination treatment strategies with RMC-6291, our mutant-selective RASG12C(ON) Inhibitor, and with immunotherapy and other cancer drugs.” The RMC-6236-001 Phase 1/1b trial is a multicen...
The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s ...
体内:RMC-6291 (200mg/kg, 口服, 每日一次, 60天) 在小鼠肿瘤模型中显著抑制肿瘤生长并诱导免疫记忆[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Clinical Trial 参考文献: [1]. Nichols R J, et al. RMC-6291, a next-generation tri-comple...